A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
← catalyst calendarSponsored by Invivyd, Inc. (industry) · IVVD — their whole pipeline →. With Novotech (Australia) Pty Limited.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Other
Enrollment
40estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-28 | actual | When the study began enrolling |
| Primary completion | May 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Biological: VYD2311
- Other: Placebo — also filed as 0.9% sodium chloride
Primary outcome
what the primary-completion date above is the date OFIncidence of TEAEs (including AEs and SAEs)
measured Through Month-6 visit
Permalink · IVVD's whole pipeline · Catalyst calendar · Every registered study · What changed